This unique facility, conceived of and pioneered by Dr. James Day and Dr. Reginald Clark in the early 1980s, has been refined and developed over the past two decades garnering it recognition around the world and bringing to you an innovative new way to conduct allergy research trials. As a fully validated and GCP compliant research environment, the EEU has been used to evaluate the onset of action
and efficacy of antihistamines, nasal corticosteroids and other investigational medications in the treatment of allergic rhinitis and resulted in studies undertaken by a majority of the multinational pharmaceutical companies involved with anti-allergic treatments. As a highly controlled indoor environment, the EEU eliminates the variables of weather, subject environment, and the changing antigenicity of seasonal ragweed so that studies can be conducted at any time of the year and subject responses to the allergen of interest can be readily evaluated. FDA and European Medicines Agency (EMEA) as a means to assess onset of action of anti-allergic treatment.
